What other stocks do shareholders of Celyad Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG) , Cellectis (CLLS) , Gilead Sciences (GILD) , Intercept Pharmaceuticals (ICPT) , ChromaDex (CDXC) , bluebird bio (BLUE) , SCYNEXIS (SCYX) , Neurocrine Biosciences (NBIX) , AbbVie (ABBV) and argenx (ARGX) .

When did Celyad Oncology IPO?

Celyad Oncology (CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

NASDAQ:CYAD

Celyad Oncology (CYAD) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free CYAD Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.40
▼
$0.65
50-Day Range: $0.59
▼
$0.85
52-Week Range: $0.46
▼
$3.07

Volume: 3,009 shs
Average Volume: N/A
Market Capitalization: $15.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Headlines Social Media

Get Celyad Oncology alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Celyad Oncology Stock (NASDAQ:CYAD)

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

CYAD Stock News Headlines

April 4, 2024 | finance.yahoo.com

Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

March 29, 2024 | seekingalpha.com

CSBR Champions Oncology, Inc.

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 17, 2024 | finanznachrichten.de

Celyad Oncology SA: Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

January 16, 2024 | finance.yahoo.com

Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

December 17, 2023 | businesswire.com

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

December 4, 2023 | finance.yahoo.com

Celyad Announces Management Change

November 14, 2023 | tmcnet.com

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 11, 2023 | lse.co.uk

Celyad Oncology Share Price (CYAD.BR)

November 9, 2023 | finanznachrichten.de

Celyad Oncology SA: Celyad Oncology reports third quarter 2023 financial results and recent business highlights

November 9, 2023 | finance.yahoo.com

Celyad Oncology reports third quarter 2023 financial results and recent business highlights

September 26, 2023 | finanznachrichten.de

Celyad Oncology SA: Celyad Oncology announces the termination of its American Depository Receipt program

September 25, 2023 | marketwatch.com

Celyad Oncology to Terminate ADR Program

September 25, 2023 | finance.yahoo.com

Celyad Oncology announces the termination of its American Depository Receipt program

September 15, 2023 | finance.yahoo.com

Celyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLC

September 12, 2023 | businesswire.com

Celyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SA

September 12, 2023 | ca.finance.yahoo.com

Celyad Oncology SA (CYAD.BR)

September 7, 2023 | finance.yahoo.com

Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC

September 4, 2023 | finanznachrichten.de

Celyad Oncology SA: Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights

September 4, 2023 | finance.yahoo.com

Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights

September 4, 2023 | investing.com

Celyad Oncology (CYADY) Earnings Dates & Reports

August 29, 2023 | finance.yahoo.com

Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments From Historical Shareholders

August 25, 2023 | finanznachrichten.de

Celyad Oncology SA: Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders

July 19, 2023 | investing.com

Celyad Oncology SA (CYADY)

May 16, 2023 | finanznachrichten.de

Celyad Oncology SA: Celyad Oncology announces receipt of Nasdaq delisting notice

May 15, 2023 | finance.yahoo.com

Celyad Oncology Announces Receipt of Nasdaq Delisting Notice

See More Headlines

Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/17/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CYAD
CUSIP: N/A
CIK: 1637890
Web: www.celyad.com
Phone: (210) 039-4100
Fax: 321-039-4141
Employees: 95
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $110,000.00
Price / Sales: 144.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.20 per share
Price / Book: 3.00

Miscellaneous

Outstanding Shares: 26,520,000
Free Float: 26,276,000
Market Cap: $15.91 million
Optionable: Not Optionable
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Georges Rawadi
Chief Executive Officer & Executive Director
David Georges
Vice President-Finance & Administration
Eytan Breman
Director-Research & Development
An Phan
Head-Legal

Key Competitors

View All Competitors

CYAD Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Celyad Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Celyad Oncology investors own include Galapagos (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), ChromaDex (CDXC), bluebird bio (BLUE), SCYNEXIS (SCYX), Neurocrine Biosciences (NBIX), AbbVie (ABBV) and argenx (ARGX).
When did Celyad Oncology IPO?: Celyad Oncology (CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

This page (NASDAQ:CYAD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Celyad Oncology (CYAD) Stock Price, News & Analysis

About Celyad Oncology Stock (NASDAQ:CYAD)

CYAD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CYAD Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info